Current challenges in HER2-positive breast cancer.

Area of Science:

• Oncology
• Medical treatment

Background:

• Trastuzumab has significantly improved outcomes for patients with HER2-positive breast cancer.
• Optimal use of trastuzumab, including in small tumors and cardiac safety, is still being defined.
• New HER2-directed therapies are evolving the treatment landscape.

Purpose of the Study:

• To summarize the latest evidence on HER2-positive breast cancer management.
• To provide insights into the optimal use of trastuzumab and newer HER2-targeted agents.
• To delineate future research and treatment perspectives.

Main Methods:

• Review of recent clinical evidence and guidelines.
• Synthesis of data on trastuzumab, pertuzumab, and trastuzumab-emtansine (T-DM1).
• Analysis of treatment strategies for early and advanced HER2-positive breast cancer.

Main Results:

• Recent evidence addresses optimal trastuzumab use in specific patient populations.
• New therapies like pertuzumab and T-DM1 offer improved efficacy.
• The treatment algorithm for HER2-positive breast cancer is continuously evolving.

Conclusions:

• Current evidence supports refined use of trastuzumab and integration of novel HER2-targeted therapies.
• Ongoing research is crucial for further optimizing treatment for HER2-positive breast cancer.
• Future perspectives involve personalized treatment approaches and novel therapeutic strategies.